Cardiomyopathy Clinical Trials
Here are the 6 most popular medical studies for cardiomyopathy
Carnitine for Carnitine Deficiency
There are some adults with skeletal muscle weakness (called "myopathy") and heart muscle weakness (called "cardiomyopathy") who have low blood levels of a compound called carnitine as a cause of their problems. Carnitine is very important to energy production in muscles. In fact, there are reports of some people with carnitine deficiency who have developed myopathy and cardiomyopathy that was completely reversed with carnitine treatment. The main objective of our project is to determine the number of patients who have carnitine deficiency as a cause of their myopathy and cardiomyopathy. The investigators will be measuring carnitine levels in 1000 patients with cardiomyopathy and will describe the specific features in all the study patients to see if there are any trends that may help us predict which patients with muscle weakness are at risk of developing low carnitine levels. The investigators will be treating patients with low carnitine levels with carnitine and observing them to see if their cardiomyopathy and their muscle weakness improve. Knowing the exact percentage of myopathy and cardiomyopathy patients with carnitine deficiency may allow for screening of patients in a cheap and targeted way to treat the serious complication of this condition, including heart failure and sudden death.
Carvedilol for Cardiomyopathy in Breast Cancer Patients
This trial is testing whether a beta blocker called carvedilol can help protect the hearts of breast cancer patients taking trastuzumab-based HER2-directed therapy, either by starting it when significant heart function decline or early signs of heart injury are noted, or preventatively before beginning trastuzumab-based therapy.
Antiarrhythmic drug
Amiodarone +1 More for Cardiomyopathy
Premature ventricular contractions (PVCs) coexist in patients with heart failure (HF) and LV dysfunction. Frequent PVCs have shown to induce a reversible cardiomyopathy (PVC-CM). This clinical pilot study will enroll 36 patients with frequent PVCs (burden >10%) and CM (LVEF <45%) and randomize them to either: 1) RFA or 2) AADs. Prior to treatment, patients will undergo a baseline cardiac MR if clinically indicated followed by 3-month observation period (optimal HF medical therapy). Changes in LV function/scar, PVC burden/arrhythmias and clinical/functional status (QOL, HF symptoms and admissions, NYHA class) and adverse events will be assessed throughout the observation period and compare with PVC suppression strategies (RFA or AAD). Similar comparison will be made between RFA and AAD treatment groups during a 12-month follow up using a Prospective Randomized Open, Blinded End-point (PROBE) study design. The treatment regimens will be compared in an intention-to-treat analysis. In addition, a total of 20,000 consecutive ambulatory ECG Holter monitors from all participating centers will be screened to identify all patients with probable diagnosis of PVC-CM. This pilot study is intended to estimate the prevalence of this clinical entity and pave the way for a large full scale randomized trial to identify best treatment strategy for patients with PVC-CM. Treating and reversing this underestimated PVC-CM may improve patient's health and subsequently decrease HF healthcare spending.
Popular filter options for cardiomyopathy trials
Dilated Cardiomyopathy Clinical Trials
View 30 Dilated Cardiomyopathy medical studies.
Behavioural Intervention
Clinical Support Pathway for Heart Enlargement
This trial will study the impact of a centralized clinical support pathway on the diagnosis & treatment of hypertension & recognition of thickened heart muscle on echos, which is associated w/ increased risk of severe pathology.
Gene Therapy
Gene Therapy for Cardiomyopathy in Friedreich's Ataxia
This trial is testing a gene therapy to treat Friedreich's ataxia, a disease that affects the heart. The therapy uses a virus to deliver the gene. It will be given intravenously to 10 people to see if it is safe and effective.
Behavioural Intervention
Biomarker-Guided Intervention for Chemotherapy Toxicity in Cancer Patients
This trial will test whether a biomarker-guided cardioprotection strategy using NTproBNP is safe and feasible for breast cancer and lymphoma patients treated with anthracyclines, as compared to usual care.
Takotsubo Syndrome Clinical Trials
View 17 Takotsubo Syndrome medical studies.
Behavioural Intervention
Biomarker-Guided Intervention for Chemotherapy Toxicity in Cancer Patients
This trial will test whether a biomarker-guided cardioprotection strategy using NTproBNP is safe and feasible for breast cancer and lymphoma patients treated with anthracyclines, as compared to usual care.
Critical Pathway for Heart Failure
The purpose of this study is to develop and implement a critical pathway to identify patients with ischemic cardiomyopathy who are candidates for an implantable cardioverter-defibrillator (ICD). This study will also determine whether the use of the critical pathway for ICDs is associated with a change in the ICD referral and implantation rate.
Angiotensin Converting Enzyme Inhibitor
Lisinopril for Heart Failure
The intent of the study is to show the potential benefits of angiotensin converting enzyme inhibitors in preventing anthracycline induced cardiotoxicity. This is a prospective, randomized, blinded and placebo-controlled clinical trial that will enroll patients who are to be treated with anthracycline chemotherapy (doxorubicin, epirubicin, idrarubicin, or mitoxantone) to either lisinopril or placebo group. The study will be performed at the Genesys Hurley Cancer Institute. The treating oncologist who intends to start the patient on anthracycline chemotherapeutic agent will provide the patient with a recruitment flyer and informed consent form and then referred to the research nurse. Subjects interested in participation, that do not meet any of the exclusion criteria, will be consented and enrolled by the research nurse prior to their first treatment with chemotherapy. Over a period of 1 to 3 weeks the study medication will be titrated in a stepwise fashion to a target of 20 mg daily, maintaining a systolic blood pressure greater than 90 mmHg. A baseline echocardiogram with strain and strain rate imaging will be obtained prior to initiation of anthracycline chemotherapy. Subsequent echocardiograms with strain and strain rate imaging will be performed every 3 months for a total of 12 months. Patients will be followed for a total of 12 months, starting on the day of enrollment. We intend to recruit a total of 200 patients. The primary endpoint of this study is a change in change in strain and strain rate parameters prior to, during, and after anthracycline chemotherapy compared to placebo. Study data will be collected and managed using the Ascension installation of REDCap (Research Electronic Data Capture). REDCap is a secure, web application designed to support data capture for research studies, providing user-friendly web-based case report forms, real-time data entry validation (e.g. for data types and range checks), audit trails and a de-identified data export mechanism to common statistical packages. Echocardiographic data will be stored in cine-loop format on a private, password protected echocardiogram viewing software and analyzed by a separate blinded cardiologist. Patients will be evaluated according to the standard oncologic evaluation. The treating oncologist will make decisions on their treatment based on their personal standards and clinical judgement.
Mesenchymal Stem Cell Therapy
Mesenchymal Stem Cell Transplantation for Heart Failure
This trial studies the side effects of donor bone marrow derived mesenchymal stem cells in patients with cardiomyopathy caused by anthracyclines. The cells may help to control symptoms of heart failure and improve heart function.
Cardiomyopathy Clinical Trials With No Placebo
View 78 cardiomyopathy medical studies that do not have a placebo group.
Behavioural Intervention
Clinical Support Pathway for Heart Enlargement
This trial will study the impact of a centralized clinical support pathway on the diagnosis & treatment of hypertension & recognition of thickened heart muscle on echos, which is associated w/ increased risk of severe pathology.
Gene Therapy
Gene Therapy for Cardiomyopathy in Friedreich's Ataxia
This trial is testing a gene therapy to treat Friedreich's ataxia, a disease that affects the heart. The therapy uses a virus to deliver the gene. It will be given intravenously to 10 people to see if it is safe and effective.
Antisense Oligonucleotide
ION-682884 for Transthyretin Amyloid Cardiomyopathy
This trial is testing a new drug to see if it can slow or stop the progression of a disease called TTR amyloid cardiomyopathy. The disease is caused by a protein called transthyretin, which is produced in the liver. The new drug, ION-682884, is designed to reduce production of the protein by the liver. The trial will last for at least 36 months, and the patients will be monitored for safety and tolerability.
View More Cardiomyopathy Trials
See another 50 medical studies focused on cardiomyopathy.
Frequently Asked Questions
Introduction to cardiomyopathy
What are the top hospitals conducting cardiomyopathy research?
When it comes to advancing the understanding and treatment of cardiomyopathy, several leading hospitals are at the forefront of groundbreaking clinical trials. Brigham and Women's Hospital in Boston leads the pack with nine active trials focused on this heart condition, along with a notable tally of 29 completed studies since their first recorded trial back in 2006. Joining them in Boston is Massachusetts General Hospital, which currently has five ongoing cardiomyopathy trials and an impressive track record of 22 previous trials, starting from as early as 2004.
Across the country in Portland, Oregon Health and Science University is making significant contributions to cardiomyopathy research with four active clinical trials and a cumulative total of 14 conducted studies since their inaugural trial in 2007. Similarly, Cedars-Sinai Medical Center in Los Angeles boasts four ongoing cardiomyopathy trials and has made valuable progress through its involvement in 16 previous investigations dating back to 2007.
Notably recognized for their expertise in cardiovascular care, Cleveland Clinic also plays a vital role by conducting cutting-edge research into cardiomyopathy. Currently undertaking four active clinical trials for this condition alone while having accomplished an impressive count of35 prior investigations since recording its first trial related to cardiomyopathy way back when i.e., around2005.
These top-tier medical institutions serve as beacons of hope for those affected by cardiomyopathy across various geographic locations. Through their dedicated efforts and innovative approaches to research, they strive towards improving outcomes for patients worldwide battling this concerning heart condition.
Which are the best cities for cardiomyopathy clinical trials?
When it comes to cardiomyopathy clinical trials, several cities emerge as leaders in research and development. Boston, Massachusetts leads the way with 22 active trials investigating treatments like Eplontersen, Tafamidis, and Breastfeeding Observational Cohort. New york, New York follows closely behind with 17 ongoing studies focused on interventions such as Solia S LBB lead and Mitral valve repair. Chicago, Illinois and Philadelphia, Pennsylvania both have 16 active trials exploring options like danicamtiv and Biomarker Guided Intervention. Lastly, Portland, Oregon offers 12 active trials examining potential breakthroughs including Tafamidis and mavacamten. These cities provide individuals with cardiomyopathy access to cutting-edge clinical trials that contribute to advancing care for this condition.
Which are the top treatments for cardiomyopathy being explored in clinical trials?
Exciting advancements are taking place in the realm of cardiomyopathy treatments, with several promising options being explored in current clinical trials. At the forefront is carvedilol, a well-established medication that has shown potential in two active trials and five all-time cardiomyopathy studies since its first listing in 2000. Another contender on the horizon is eplontersen, making waves with two ongoing trials dedicated to cardiomyopathy. Its recent introduction to the medical scene in 2020 has sparked interest and hope for future treatment possibilities. Additionally, an intervention involving a Population Health Coordinator is underway, showing promise as it enters its first trial for cardiomyopathy treatment. Lastly, AAVrh.10hFXN—an adeno-associated virus gene transfer vector—is also entering uncharted territory with one active trial focused specifically on treating this condition. These cutting-edge approaches bring us closer to finding effective solutions for patients battling cardiomyopathy worldwide.
Note: "Intervention: Population Health Coordinator" was not specified as a treatment option but included due to lack of alternative information provided by users
What are the most recent clinical trials for cardiomyopathy?
Exciting advancements are underway in the field of cardiomyopathy, with recent clinical trials offering promising prospects for patients. One such trial focuses on Aficamten (CK-3773274), which investigates different dosages (5 mg, 10 mg, 15 mg, and 20 mg) to determine its efficacy in treating cardiomyopathy. Additionally, RP-A601 is being studied in a Phase 1 trial to evaluate its potential benefits for individuals with this condition. Another notable study explores Cohort 1's impact on cardiomyopathy through a Phase 2 investigation. Mavacamten and Eplontersen are also being examined in separate Phase 3 trials as potential therapies for this cardiac disorder. These exciting developments hold promise for improving the lives of those affected by cardiomyopathy.
What cardiomyopathy clinical trials were recently completed?
Recently completed clinical trials for cardiomyopathy have shown promising results in the search for effective treatments. Notably, Columbia University's trial investigating Empagliflozin reached completion in March 2022. Similarly, Cytokinetics concluded its study on CK-3773274 (10 - 30 mg) in January 2020. Furthermore, Eidos Therapeutics, a BridgeBio company, made significant progress with their acoramidis trial which wrapped up in March 2019. These advancements demonstrate the commitment of researchers and offer hope to individuals affected by cardiomyopathy who are eagerly awaiting new therapeutic options.